 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...2122232425262728293031...235236» |
- PS101 / Exact Therap
First-in-human study of acoustic cluster therapy consisting of PS101 combined with chemotherapy and insonation in patients with liver metastases of colorectal cancer origin (Section 36) - Mar 5, 2024 - Abstract #AACR2024AACR_7563;
P1
Following preclinical activity in xenograft models, the ongoing first in human study of ACT in patients with colorectal cancer has shown clinical translation of differential activity in insonated metastasis. Reference:Reference: 1.Bush N et al Front Pharmacol 2019, 10:1299
- PF-04136309 / Pfizer
Determination of permissive and restraining cancer-associated fibroblast (DeCAF) subtypes (Section 36) - Mar 5, 2024 - Abstract #AACR2024AACR_7555;
P1
Analysis of a phase Ib trial FOLFIRINOX in combination with a CCR2 inhibitor (PF-04136309; NCT01413022) , we found that in patients with classical tumors, increasing permCAF probability was associated with response (r = -0.688, p<0.001)...DeCAF subtypes are associated with histological subtype in MESO (p = 0.021) and grade in KIRC (p = 0.056). Taken together, DeCAF subtypes explain the role of CAF subtypes in patients, provide a foundation for the translation of preclinical studies, and facilitate the design of future therapeutic approaches and clinical trials.
- Analysis of the landscape of cancer-associated neurons (CANs) in diverse cancers through retrograde tracing and single cell molecular profiling (Section 10) - Mar 5, 2024 - Abstract #AACR2024AACR_7453;
In summary, our comprehensive approach has elucidated the role of neurons in PDAC, melanoma, pancreatitis, and metastasis, leveraging innovative tools for studying the molecular programs of CANs at the single-cell level. These insights not only unveil novel mechanisms orchestrated by neuronal activity but also pave the way for imminent clinical trials, aiming to combat PDAC by targeting cancer-associated neurons.
- 5-fluorouracil / Generic mfg.
Monitoring early chemotherapy response in murine pancreatic ductal adenocarcinoma using non-invasive hyperpolarized magnetic resonance spectroscopic imaging with 13C-pyruvate (Section 8) - Mar 5, 2024 - Abstract #AACR2024AACR_7292;
We have applied a non-invasive approach for detection of metabolic changes under chemotherapy in murine PDAC. These findings will contribute in the long term to the establishment of predictive imaging biomarkers for PDAC.
- Hyleukin-7 (efineptakin alfa) / Genexine, NeoImmuneTech
rhIL-7-hyFc (efineptakin-alfa, NT-I7) increases tumor-specific CD8+ T cells despite FOLFOX cytotoxicity effect (Section 4) - Mar 5, 2024 - Abstract #AACR2024AACR_7009;
However, adding FOLFOX does not affect the NT-I7-driven increase of tumor-specific CD8+ T cells within the tumor. Taken together, our data demonstrate that FOLFOX does not compromise NT-I7's ability to increase tumor-specific T cells within the tumor and the combination enhances the anti-tumor response irrespective of the timing of NT-I7 administration.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Combination of FOLFIRI (5-FU, Leucovorin, and Irinotecan) and ProAgio on colon cancer growth and metastasis (Section 23) - Mar 5, 2024 - Abstract #AACR2024AACR_6727;
Taken together, our data demonstrate that FOLFOX does not compromise NT-I7's ability to increase tumor-specific T cells within the tumor and the combination enhances the anti-tumor response irrespective of the timing of NT-I7 administration. Our study offers encouraging observations that ProAgio plus FOLFIRI can suppress colon cancer growth and metastasis by inhibiting ?v?3 preclinically and may provide a novel therapeutic combination for the management of colon cancers.
- Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b-2 trial (Section 49) - Mar 5, 2024 - Abstract #AACR2024AACR_6662;
Our study offers encouraging observations that ProAgio plus FOLFIRI can suppress colon cancer growth and metastasis by inhibiting ?v?3 preclinically and may provide a novel therapeutic combination for the management of colon cancers. Abstract is embargoed at this time.
- High tumor monocyte content predicts long-term survival for patients with operable oesophageal cancer treated with neoadjuvant immunochemotherapy in the LUD2015-005 trial (Section 49) - Mar 5, 2024 - Abstract #AACR2024AACR_6653;
Abstract is embargoed at this time. Abstract is embargoed at this time.
- 5-fluorouracil / Generic mfg.
Comparative studies of chemotherapy and immuno-oncology combinations in multiple mouse syngeneic tumor models (Section 42) - Mar 5, 2024 - Abstract #AACR2024AACR_6554;
Specifically, we observed that the SOC/ICI combinations resulted in enhanced antitumor activities compared to single-agent treatments in many of the models. These data, particularly specific SoC combination regimens that combine well with ICIs in each disease, are useful for optimizing promising combination approaches for clinical development and will be presented here.
- STC-1010 / Brenus Pharma
Efficacy of the STC-1010 a new allogenic cancer vaccine in different colorectal cancer models (Section 39) - Mar 5, 2024 - Abstract #AACR2024AACR_6526;
In addition, mSTC-1010 associated with immunostimulant (cyclophosphamide and mGM-CSF), combined or not with chemotherapy (FOLFOX or FOLFIRI) led to a significant decrease of tumor volume, a M1-oriented macrophage response (immunohistochemical, iNOS/CD163 >1), and an increase of T lymphocyte infiltration...The good tolerability and reproducible efficiency of the STC-1010 vaccine in these different clinical models allow to plan a first-in-human phase I/II clinical trial for metastatic CRC(mCRC) patients. A dose-escalation and cohort extension phase I followed by a phase IIa with STC-1010 plus immunostimulant, associated to mFOLFOX6 w/o bevacizumab, will be performed for MSS mCRC patients to evaluate the safety and preliminary effectiveness in human.
- Organoids to predict treatment response in metastatic colorectal cancer (OPTIC) (Section 45) - Mar 5, 2024 - Abstract #AACR2024AACR_6462;
OPTIC will enhance the clinical application of PDOs by defining thresholds for PDO sensitivity and analyzing the diagnostic power for different treatments. To enable personalized treatment in clinical practice, PDO screening should guide mCRC treatment and result in enhanced chance of response and reduced over- and mistreatment.
- Opdivo (nivolumab) / Ono Pharma, BMS
A pilot clinical trial of neoadjuvant modified FOLFIRINOX plus nivolumab in borderline resectable pancreas cancer (Hall GH - Ground Level - Convention Center) - Mar 5, 2024 - Abstract #AACR2024AACR_6028;
To enable personalized treatment in clinical practice, PDO screening should guide mCRC treatment and result in enhanced chance of response and reduced over- and mistreatment. Abstract is embargoed at this time.
- L-pampo / CHA Vaccine Institute
L-pampo (Section 28) - Mar 5, 2024 - Abstract #AACR2024AACR_5479;
To compare the anti-tumor efficacy of L-pampo and conventional cytotoxic chemotherapy, we treated tumor-bearing mice with FOLFOX or paclitaxel as SoC regimen, respectively... This study suggests that L-pampo, a novel TLR2/3 agonist, can be a potent anti-tumor agent, improving the anti-tumor efficacy of ICIs in cold tumors with enhanced anti-tumor immunity and minimal toxicities than conventional chemotherapies.
- Opdivo (nivolumab) / Ono Pharma, BMS, osemitamab (TST001) / Transcenta
A Phase I/IIa clinical trial (TranStar101) to evaluate the safety, tolerability and pharmacokinetics of OSEMITAMAB administered as monotherapy or in combination with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors (Section 49) - Mar 5, 2024 - Abstract #AACR2024AACR_5200;
This study suggests that L-pampo, a novel TLR2/3 agonist, can be a potent anti-tumor agent, improving the anti-tumor efficacy of ICIs in cold tumors with enhanced anti-tumor immunity and minimal toxicities than conventional chemotherapies. Abstract is embargoed at this time.
- CimaVax EGF (EGF-PTI) / In3Bio, CIMAB
A Phase 0 Study of EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer (Section 49) - Mar 5, 2024 - Abstract #AACR2024AACR_5194;
Abstract is embargoed at this time. Abstract is embargoed at this time.
- 5-fluorouracil / Generic mfg.
Intestinal microbiome with chemotherapy response and RAS mutation in patients with advanced or metastatic colorectal cancer: a pilot, exploratory study (Section 45) - Mar 5, 2024 - Abstract #AACR2024AACR_4966;
All patients were treated with first-line systemic therapy; FOLFOX (5-fluorouracil and oxaliplatin)-based (n=13) and FOLFIRI (5-fluorouracil and irinotecan)-based chemotherapy (n=2)...Regarding the association of intestinal microbiome with RAS mutation, Bray curtis and weighted unifrac analyses revealed significant differences in beta diversity; higher incidence of Faecalibacterium, Lactobacillus, Prevotella, Anaerofilum, and UCG-005 in the RAS-wild type mCRC, while Bacteroides, Collinsella, Holdemanella, and Anaerostipes in RAS-mutated mCRC.This pilot study suggests the prognostic value of gut microbiomes and its association with RAS mutation in patients with mCRC treated with first line systemic therapy. A microbial functional study with immune cytokine change is planned to confirm these findings in future.
- Vectibix (panitumumab) / Amgen
Genomic alterations on first-line panitumumab plus FOLFIRI in metastatic colorectal cancer (Section 42) - Mar 5, 2024 - Abstract #AACR2024AACR_4927;
P2
Moreover, our data show that basal SC GAs rarely evolve to CL GAs at progression disease and do not affect survival of pts with anti-EGFR/chemotherapy treatment. An update will be provided at the congress.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Employing widening funds to address inequity in cancer research - example of the STEPUPIORS collaborative rectal cancer project (Section 1) - Mar 5, 2024 - Abstract #AACR2024AACR_4531;
The results highlight that disparities in cancer outcomes and health equity might only be addressed by progressing beyond descriptions of said outcomes and taking specific action. Systematic, long-term strategic initiatives and collaborations among relevant stakeholders and ethical, legal and societal structures are needed in more countries.
- onvansertib (PCM-075) / Cardiff Oncology, Avastin (bevacizumab) / Roche
A phase 1b/2 clinical study of onvansertib in combination with FOLFIRI/bevacizumab revealed a new role of PLK1 in regulating the hypoxia pathway in KRAS-mutant colorectal cancer (Section 27) - Mar 5, 2024 - Abstract #AACR2024AACR_4049;
P1/2
In a Phase 1b/2 study, mKRAS mCRC patients with prior exposure to oxaliplatin (with or without Bev) were treated with Onv (Days 1-5 and 15-19) in combination with FOLFIRI/Bev (Days 1 and 15) of each 28-day cycle (NCT03829410)... Onv + FOLFIRI/Bev resulted in greater clinical benefit in Bev- na
- 5-fluorouracil / Generic mfg.
Role of O-GlcNAc conjugation and TS translational repression in 5-FU/LV resistance in CRC and CF10 response (Section 26) - Mar 5, 2024 - Abstract #AACR2024AACR_3995;
The causes of 5-FU+LV resistance are multi-factorial and include TS overexpression induced by 5-FU+LV treatment that may be mediated by O-GlcNAc conjugation. We demonstrated that CF10 is more potent than 5-FU, and importantly its potency advantage is enhanced in cells selected for 5-FU+LV resistance.
- Drug-induced cancer cell secretome promotes resistance in colon cancer (Section 26) - Mar 5, 2024 - Abstract #AACR2024AACR_3989;
Additionally, in zebrafish xenograft, we found that 5-FU-R colon cancer cells cultured with 5-FU-induced secretome showed higher tail-vein metastatic burden compared to the 5-FU-R cells cultured with DMSO-induced secretome. This provides a background to further study in detail the therapy-induced resistance as well as dormancy in colorectal cancer which will help to develop approaches to prevent or reverse chemoresistance in patients who receive systemic therapy for mCRC.
- DXC-005 / Hangzhou DAC Biotech
A MUC1 antibody-conjugated with a tubulysin B analog, DXC005, demonstrates excellent synergistic effect in combination with gemcitabine for treatment of pancreatic tumors (Section 22) - Mar 5, 2024 - Abstract #AACR2024AACR_3944;
The preferred regimen includes gemcitabine combined with albumin paclitaxel or FOLFIRINOX (5-FU+Oxaliplatin+Irinotecan)...All groups of treatment are tolerated well, no abnormal animal behavior and body weight loss were observed in the study. The above results concluded that DXC005 combined with Gemcitabine can achieve synergistic effect even with reduced dose of Gemcitabine, which will serve as a support for synergistic application in clinical studies.
- aplitabart (IGM-8444) / IGM Biosciences
Novel combinations of aplitabart, a DR5 agonist IgM antibody, with ADCs or chemotherapeutic agents lead to robust anti-tumor responses in solid tumor models (Section 23) - Mar 5, 2024 - Abstract #AACR2024AACR_3899;
P1
These results support the combination of DR5 agonist IgM antibodies with agents known to upregulate DR5 expression on solid tumors. Aplitabart is currently under evaluation in a randomized clinical study in combination with FOLFIRI + bevacizumab in comparison with FOLFIRI + bevacizumab in patients with colorectal cancer (NCT04553692).
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
A phase I study of CPI-613 (devimistat) in combination with chemoradiation in patients with pancreatic ductal adenocarcinoma (Section 49) - Mar 5, 2024 - Abstract #AACR2024AACR_3879;
Aplitabart is currently under evaluation in a randomized clinical study in combination with FOLFIRI + bevacizumab in comparison with FOLFIRI + bevacizumab in patients with colorectal cancer (NCT04553692). Abstract is embargoed at this time.
- KRAS co-mutational landscape dictates treatment outcomes in pancreatic cancer (PC) patients (Section 45) - Mar 5, 2024 - Abstract #AACR2024AACR_3805;
This study provides insights into the genetic makeup of patients with KRAS mutations and how co-mutation with TP53 affects outcomes of SoC treatments. It highlights the need for comprehensive genetic profiling to make better therapy decisions.Table 1: Evaluation of KRAS mutational landscape in PC and its impact on treatment outcomes.
- Real-world validation of the PurIST classifier demonstrates enhanced therapy selection for pancreatic ductal adenocarcinoma (PDAC) patients (Section 45) - Mar 5, 2024 - Abstract #AACR2024AACR_3803;
In this real-world cohort of advanced PDAC patients, we showed that classical patients with low ECOG scores had superior OS with 1L FFX treatment compared to 1L GnP. These findings demonstrate the potential for PurIST to aid in optimal treatment selection for patients with advanced PDAC.
- mitazalimab (ADC-1013) / Alligator Biosci
Mitazalimab, a potent CD40 agonist in combination with FOLFIRINOX demonstrates changes consistent with increased immune activation in TME and peripheral blood in a preclinical pancreatic cancer tumor model (Section 38) - Mar 5, 2024 - Abstract #AACR2024AACR_3769;
P1b/2
The combination of mitazalimab and FOLFIRINOX resulted in an increased tumoricidal immune profile, including a marked increase in effector CD8+ T cells compared to the individual therapies. Overall, these preclinical data support the chosen dosing regimen of mitazalimab and modified FOLFIRINOX in the OPTIMIZE-1study and underline the synergistic potential of this combination for an improved antitumor response.
- 5-fluorouracil / Generic mfg.
Predictive biomarkers for neoadjuvant FLOT4 chemotherapy response in gastroesophageal cancer: Results of multi-omics approach (Section 44) - Mar 5, 2024 - Abstract #AACR2024AACR_3670;
The identified genes and pathways may serve as potential biomarkers for predicting treatment outcomes.Future Directions: By the time of the conference, we anticipate including a more extensive patient cohort with complete response or no response to FLOT4, and comparative analyses with a FOLFOX treatment group. The integration of forthcoming WES, methylation, miRNA, and proteomics data will provide a more comprehensive molecular predictive model.
- Opdivo (nivolumab) / Ono Pharma, BMS
Predictive value of tumor mutational burden (TMB) in patients with metastatic microsatellite-stable (MSS) colorectal cancer (CRC) given first-line oxaliplatin-based chemotherapy and immune checkpoint blockade (ICB) (Section 44) - Mar 5, 2024 - Abstract #AACR2024AACR_3669;
P2
They were randomly assigned to the control group of FLOX (oxaliplatin, 5-fluorouracil, folinic acid) Q2W or the experimental group of alternating 2 cycles each of FLOX Q2W and nivolumab Q2W, with prespecified break periods. TMB >5 mut/Mb was associated with tumor KRAS or BRAF driver mutation and remarkably long PFS in first-line treatment of patients with abdominal metastases from MSS-CRC with alternating short-course oxaliplatin-based chemotherapy and ICB.
- Unlocking the potential of miRNA sequencing for early detection and monitoring of pancreatic cancer progression and recurrence (Section 35) - Mar 5, 2024 - Abstract #AACR2024AACR_3510;
To identify biomarkers for PC progression, we developed from the Gemcitabine-sensitive MIA-PaCa-2 (MP2) cell line the Gemcitabine and FOLFIRINOX resistant MP2-GR cell line...The miRNA set was used to predict both PC progression after treatment, and recurrence. We are currently refining this data set to increase its predictive sensitivity and widen our patient data set comparison to further elucidate this approach in a clinical setting.
- Multi-dimensional patient-derived organoid analysis highly correlates with progression-free survival of pancreatic cancer patients in a retrospective clinical trial (Section 9) - Mar 5, 2024 - Abstract #AACR2024AACR_3162;
Using a fully characterized a PDAC organoid panel (n=8) we matched our PDO analysis with retrospective clinical patient response to standard of care therapies (gemcitabine-paclitaxel and FOLFIRINOX)...Taken together, our approach increased the clinical translatability of PDOs by more accurately recapitulating and measuring the complexity of human tumors. This work highlights the potential applications (extendable to other tumor types) and clinical translatability of our approach in drug discovery and clinical care, in the emerging era of personalized medicine.
- Genetic ablation of microRNA-10b improves treatment outcomes in mouse models of pancreatic cancer (Section 19) - Mar 5, 2024 - Abstract #AACR2024AACR_3002;
These unique features endow PDAC tumors with an array of innate resistance mechanisms against standard-of-care (SOC) chemotherapy: gemcitabine/nab-paclitaxel or FOLFIRINOX...Notably, we observed a more durable response in treated female KPC; Mir-10bKO animals (n = 4 ) compared to any other experimental group (n > 5). We are currently performing tissue and molecular analyses to identify direct target genes involved in chemoresistance and sex-specific modulation of treatment response.
- ompenaclid (RGX-202) / Inspirna, EMD Serono
Anti-tumor efficacy of ompenaclid, a creatine transporter inhibitor, in KRAS mutant tumors, including NSCLC (Section 18) - Mar 5, 2024 - Abstract #AACR2024AACR_2984;
Notably, and consistent with findings in CRC, efficacy in NSCLC was more robust in RAS mutant cancer models, relative to those bearing KRAS WT tumors. Metabolite analysis of the plasma of tumor-bearing mice at baseline revealed that mice harboring RAS mutant tumors had higher levels of p-creatine and lower levels of ATP, indicating that RAS mutant tumors utilize higher amounts of ATP, which may be converted to phosphocreatine by tumoral CKB, as confirmed by qPCR analysis.
- Recentin (cediranib) / AstraZeneca, Avastin (bevacizumab) / Roche
Targeted proteomics and next-generation sequencing (NGS) for biomarker discovery in metastatic colorectal cancer (mCRC) (Section 39) - Mar 5, 2024 - Abstract #AACR2024AACR_2474;
P2/3
Our preliminary findings for this cohort indicate the benefit of the use of multi-modal methodologies to inform better strategies for patient stratification and precision medicine, though further assessment of proteogenomic characteristics is needed. This data may inform future clinical development and guide patient eligibility to clinical trials and possible treatment sequencing for ADCs.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Modulation of the MSS and MSI colorectal cancer immune microenvironment with FOLFOX and FOLFIRI -/+ anti-PD-1 immunotherapy (Section 47) - Mar 5, 2024 - Abstract #AACR2024AACR_2437;
Most patients receive 5-FU (F) and folinic acid (FOL) combined with oxaliplatin (OX), irinotecan (IRI), or both (OXIRI)...These data point to a FOX-specific mechanism by which CD8+ T cell infiltration into MSS mCRC tumors is enhanced, but their activation is halted potentially by GM-CSF suppression and/or type 1 cDC depletion in the TME. These findings contribute to our understanding of the mechanisms of chemotherapy-dependent immune modulation and bring the field closer to harnessing these effects for therapeutic gain.
- Opdivo (nivolumab) / Ono Pharma, BMS
Dissecting pancreatic cancer tumor-immune microenvironment crosstalk using spatial transcriptomics (Section 46) - Mar 5, 2024 - Abstract #AACR2024AACR_2302;
P2
This enables the discovery of novel immune response biomarkers and potential therapeutic avenues to target tumor and microenvironment interactions.Trial Registration: DF/HCC protocol 18-179: Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer. NCT03563248Ethics Approval: All studies presented were approved by the Dana-Farber/Harvard Cancer Center IRB protocols 18-179.
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial initiation date: A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL) (clinicaltrials.gov) - Mar 5, 2024
P3, N=680, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
NCT03563248Ethics Approval: All studies presented were approved by the Dana-Farber/Harvard Cancer Center IRB protocols 18-179. Initiation date: Jan 2024 --> Apr 2024
- ||| Ziihera (zanidatamab-hrii) / Jazz
Enrollment closed, Enrollment change: ZWI-ZW25-201: A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer (clinicaltrials.gov) - Mar 5, 2024
P2, N=74, Active, not recruiting, Sponsor: Jazz Pharmaceuticals
Initiation date: Jan 2024 --> Apr 2024 Recruiting --> Active, not recruiting | N=362 --> 74
- | Trial completion, Enrollment change, Metastases: BCC-RAD-13: Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer (clinicaltrials.gov) - Mar 5, 2024
P2, N=5, Completed, Sponsor: University of Louisville
Recruiting --> Active, not recruiting | N=362 --> 74 Recruiting --> Completed | N=28 --> 5
- || petosemtamab (MCLA-158) / Merus
Trial completion date, Trial primary completion date, Metastases: MCLA-158-CL01: A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 4, 2024
P1/2, N=360, Recruiting, Sponsor: Merus N.V.
Recruiting --> Completed | N=28 --> 5 Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2023 --> Jun 2024
- || Retrospective data, Review, Metastases: Comparative efficacy and safety of multimodality treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: patient-level network meta-analysis. (Pubmed Central) - Mar 4, 2024
In terms of PFS, TACE+Len showed better benefits than lenvatinib, donatinib, and tremelimumab+durvalumab...The SUCRA score for OS ranked HAIC-FO+sorafenib as the best treatment option among all multimodality treatments in hepatitis B, MVI, or PVTT with EHS and AFP 400 ?g/L subgroups. HAIC-FO and HAIC-FO+sorafenib are statistically better options for unresectable hepatocellular carcinoma with PVTT among the multimodality treatments, and their effective and safe implementation may provide the best outcomes for HCC-PVTT patients.
- | Journal, Real-world evidence, Real-world: FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel as First Line Treatment in Pancreatic Cancer: A Real-World Comparison. (Pubmed Central) - Mar 4, 2024
There was no difference in outcomes between patients who received FOL and those who received GnP. Unexpectedly, no greater FOL-related toxicity was found, probably due to the dose reduction.
- | 5-fluorouracil / Generic mfg.
Journal: Maintenance of the Branched-Chain Amino Acid transporter LAT1 Counteracts Myotube Atrophy following Chemotherapy. (Pubmed Central) - Mar 4, 2024
However, RNAi-mediated depletion of NEdd4, the protein ligase responsible for ubiquitin-dependent degradation of LAT1, attenuated the effects of chemotherapy on BCAA concentrations, anabolic signaling, protein synthesis and myofibrillar protein abundance. Thus, if our findings are validated in preclinical models, interventions regulating muscle amino acid transporters might represent a promising strategy to treat cachexia.
- | Trial termination: Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (clinicaltrials.gov) - Mar 4, 2024
P1, N=2, Terminated, Sponsor: OHSU Knight Cancer Institute
Thus, if our findings are validated in preclinical models, interventions regulating muscle amino acid transporters might represent a promising strategy to treat cachexia. Active, not recruiting --> Terminated; Low accrual
- | Trial completion date: A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) (clinicaltrials.gov) - Mar 3, 2024
P1, N=422, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Terminated; Low accrual Trial completion date: Aug 2026 --> Apr 2026
- ||| onvansertib (PCM-075) / Cardiff Oncology
Enrollment open, Trial initiation date, Combination therapy, Metastases: Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants with a KRAS or NRAS Mutation (clinicaltrials.gov) - Mar 3, 2024
P2, N=90, Recruiting, Sponsor: Cardiff Oncology
Trial completion date: Aug 2026 --> Apr 2026 Not yet recruiting --> Recruiting | Initiation date: Nov 2023 --> Feb 2024
- | Oncorine (recombinant human adenovirus type 5) / Mergen Ltd.
Enrollment open, Trial completion date, Trial primary completion date: Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma (clinicaltrials.gov) - Mar 3, 2024
P4, N=66, Recruiting, Sponsor: Beijing Tsinghua Chang Gung Hospital
Not yet recruiting --> Recruiting | Initiation date: Nov 2023 --> Feb 2024 Not yet recruiting --> Recruiting | Trial completion date: Apr 2024 --> Apr 2026 | Trial primary completion date: Apr 2024 --> Apr 2026
- || M9140 / EMD Serono
Enrollment change, Trial completion date, Trial primary completion date, Metastases: Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) (clinicaltrials.gov) - Mar 3, 2024
P1, N=180, Recruiting, Sponsor: EMD Serono Research & Development Institute, Inc.
Not yet recruiting --> Recruiting | Trial completion date: Apr 2024 --> Apr 2026 | Trial primary completion date: Apr 2024 --> Apr 2026 N=31 --> 180 | Trial completion date: Nov 2023 --> May 2025 | Trial primary completion date: Nov 2023 --> Apr 2024
- NEOADJUVANT FOLFOXIRI FOR COLORECTAL LIVER METASTASES: INSIGHTS FROM A MULTI-INSTITUTIONAL STUDY (Poinciana 1/2) - Mar 2, 2024 - Abstract #AHPBA2024AHPBA_276;
- || magrolimab (ONO-7913) / Ono Pharma
Trial primary completion date, Combination therapy, Metastases: ELEVATE CRC: Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Mar 2, 2024
P2, N=135, Recruiting, Sponsor: Gilead Sciences
N=31 --> 180 | Trial completion date: Nov 2023 --> May 2025 | Trial primary completion date: Nov 2023 --> Apr 2024 Trial primary completion date: Feb 2024 --> Mar 2025